文献速递血栓与止血

新型人源化FIX/FX血友病A小鼠模型用于FVIIIa模拟双特异性抗体临床前评估

A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies.
PubMed 文献 · Blood Adv · 2026-01-01

研究建立人源化FIX/FX双敲入先天性血友病A(HuHA)小鼠模型,以克服艾美赛珠单抗等FVIIIa模拟双特异性抗体因种属特异性受限的体内功能评估难题。该模型组成性表达功能性人FIX和人FX,水平相当于或高于人血浆浓度。凝血酶生成试验显示重组人FVIII和艾美赛珠单抗剂量依赖性改善凝血酶生成峰值,尾剪试验提示两种治疗药物体内止血效应,但需谨慎解读。

要点

  • HuHA小鼠组成性表达功能性人FIX和FX,水平相当于或高于人血浆浓度
  • 凝血酶生成试验显示rhFVIII和艾美赛珠单抗剂量依赖性改善凝血酶生成峰值
  • 尾剪试验提示两种药物体内止血效应,但模型局限性需谨慎解读

核心结论

  • HuHA小鼠模型可在FVIII缺陷背景下组成性表达功能性人FIX和人FX,可能为人特异性血友病A治疗药物提供新的临床前评估平台。

研究设计与样本

  • 通过替换小鼠FIX/FX基因为人同源基因并破坏小鼠FVIII,建立hFIX/hFX双敲入先天性血友病A模型(HuHA)小鼠。

主要发现

  • HuHA小鼠组成性表达功能性hFIX和hFX,水平相当于或高于人血浆浓度。
  • 凝血酶生成试验显示重组人FVIII和艾美赛珠单抗均剂量依赖性改善凝血酶生成峰值。
  • 尾剪试验提示两种治疗药物在体内具有潜在止血效应,但鉴于模型局限性需谨慎解读。

临床怎么用

  • 该模型可能用于人特异性血友病A治疗药物(如FVIIIa模拟双特异性抗体)的临床前功能评估。

局限性

  • 尾剪试验结果应谨慎解读,因模型存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of nonfactor products such as emicizumab, a bispecific antibody that mimics the cofactor function of activated factor VIII (FVIIIa) by bridging FIXa and FX, has significantly reduced bleeding episodes in people with hemophilia A (HA). However, emicizumab high species specificity in its FVIIIa-mimetic cofactor activity has limited in vivo functional evaluation to an acquired HA nonhuman primate model or congenital HA mouse model with infusion of human FIX (hFIX) and hFX proteins. To overcome the limitations of existing models, we generated hFIX/hFX double-knockin congenital HA model (humanized HA [HuHA]) mice. HuHA mice were established by the replacement of mouse FIX/FX genes with their human homologs and by the disruption of mouse FVIII. In HuHA mice, functional hFIX and hFX are constitutively expressed at levels equivalent to, or higher than, human plasma concentrations. Thrombin generation assays demonstrated dose dependently improved peak thrombin generation by both recombinant hFVIII (rhFVIII) and emicizumab. These HuHA mice were found to express sufficient levels of hFIX and hFX to support functional evaluation of rhFVIII and emicizumab activities. Furthermore, the tail-clip assay suggested potential hemostatic effects of both therapeutic agents in vivo, although the findings should be interpreted with caution given the limitations of the model. This novel mouse model, in which functional hFIX and hFX are constitutively expressed on an FVIII-deficient background, may provide a new platform for the preclinical evaluation of human-specific therapeutics for HA.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Watanabe T, Sakata A, Matsumoto N, et al. A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies. Blood Adv. 2026. PMID: 42275566. doi:10.1182/bloodadvances.2025018528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。